Tailoring targeted therapy to DNA repair-defective High-Grade Serous Ovarian Cancer [ 2014 - 2016 ]

Research Grant

Researchers: A/Pr Clare Scott (Principal investigator) ,  Dr Matthew Wakefield ,  Prof David Bowtell ,  Prof Paul Waring

Brief description Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and should be susceptible to new PARP inhibitor therapy, yet not all those respond. By developing a new model of studying human ovarian cancers in mice, we can discover markers to predict which ovarian cancers will respond best to these exciting new treatments.

Funding Amount $AUD 802,247.15

Funding Scheme Project Grants

Notes Standard Project Grant